bioRxiv Science⌕ Search

Biology subjects

Swartz, J. R.

Publications and source records attributed to Swartz, J. R..

3 recordsLinked to original sources

Design-driven optimization of low-cost reagent formulations for reproducible and high-yielding cell-free gene expression

Access to recombinant proteins is vital in basic science and biotechnology research. Cell-free gene expression systems provide one approach to address this need, but widespread utilization remains limited by the cost, complexity, and inconsistency of current platforms. To address these limitations, we carry out a multi-dimensional definitive screening design to reduce the number of reagent components and remove costly secondary energy substrates. From more than 1,200 reagent formulations, we discover a simple and reproducible system based on 12 components. The optimized reagent formulation can produce 2.4 {+/-} 0.3 g/L of protein product at the 15-L scale ([~]$55/gprotein) and 3.7 {+/-} 0.2 g/L ([~]$36/gprotein) at the 4-mL scale with oxygen supplementation. This provides an 84 to 99% reduction in cost over previous cell-free reagent formulations. We further show that the optimized reagent formulation can produce nucleoside triphosphates from nucleotides and ribose and that it is robust to failure across batches of cell lysates, users/locations, and in the synthesis of different proteins. Specifically, we demonstrate the production of fifteen therapeutically relevant products, including full-length aglycosylated monoclonal antibodies. We anticipate that our optimized reagent formulation will further democratize the use of cell-free systems for protein manufacturing and synthetic biology applications.

synthetic biology↗

Secretion and Periplasmic Activation of a Potent Endonuclease in E. coli

Sm Endonuclease (SmEn) is a promiscuous, highly active nuclease widely used in protein purification, 2D protein gels, and gene and cell therapy. We aimed to recombinantly and economically produce this reagent using E. coli. Despite widespread application of E. coli for recombinant production of proteins, cytoplasmic expression of this protein resulted in no activity accumulation. We therefore investigated translocation of SmEn to the periplasm of E. coli by evaluating several signal sequences, E. coli host cells, and incubation conditions. For rapid feedback, we developed a crude lysate-based nuclease activity assay that enabled convenient screening and identified suitable conditions for active SmEn accumulation. Signal sequence selection was most influential with additional benefit gained by slowing synthesis either using the transcriptionally weakened strain, C43 (DE3) or by reducing incubation temperature. While our study provides valuable insights for optimizing a nuclease translocation and reducing production costs, more research is needed to explore the influence of mRNA secondary structure at the translation initiation region on protein expression and translocation. Overall, our rapid screening assay facilitated the development of an effective production process for a protein with potential cytoplasmic toxicity as well as the need of disulfide bond formation.

systems biology↗

An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics

This study describes the cell-free biomanufacturing of a broad-spectrum antiviral protein, griffithsin (GRFT) such that it can be produced with consistent purity and potency in less than 24 hours. We demonstrate GRFT production using two independent cell-free systems, one plant and one microbial. Griffithsin purity and quality were verified using standard regulatory metrics. Efficacy was demonstrated in vitro against SARS-CoV-2 and HIV-1 and was nearly identical to that of GRFT expressed in vivo. The proposed production process is efficient and can be readily scaled up and deployed anywhere in the world where a viral pathogen might emerge. The current emergence of viral variants has resulted in frequent updating of existing vaccines and loss of efficacy for front-line monoclonal antibody therapies. Proteins such as GRFT with its efficacious and broad virus neutralizing capability provide a compelling pandemic mitigation strategy to promptly suppress viral emergence at the source of an outbreak.

bioengineering↗